EUVIMEDEUVIMED entdecken
Open Access

Association of Medicaid Expansion With Timely Receipt of Treatment and Survival Among Patients With HR-Negative, HER2-Positive Breast Cancer

Kewei Sylvia Shi, Xu Ji, Changchuan Jiang, Kathryn J Ruddy, Sharon M Castellino, K Robin Yabroff, Xuesong Han

Journal of the National Comprehensive Cancer Network · 2024

DOI: 10.6004/jnccn.2024.7041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2024. Verfasst von Kewei Sylvia Shi und 6 weiteren Autor:innen. Beteiligte Einrichtung: 1Surveillance and Health Equity Science, American Cancer Society, Atlanta, GA. Hauptthemen laut MEDLINE: Breast Neoplasms, Medicaid, Erb-b2 Receptor Tyrosine Kinases, Patient Protection and Affordable Care Act. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Hormone receptor (HR)–negative, HER2-positive (also called HER2-enriched) breast cancer has no worse prognosis than other breast cancers if it is treated with HER2-targeted therapy. Medicaid expansion under the Affordable Care Act (ACA) has been shown to be associated with improved access to care and outcomes for many cancers, but its association with receipt of care for HR-negative, HER2-positive breast cancer is unknown. We examined the association of Medicaid expansion with receipt of guideline-concordant treatment, time to treatment initiation, and survival among nonelderly women newly diagnosed with HR-negative, HER2-positive breast cancer. Patients and Methods: Women aged 18 to 62 years newly diagnosed with HR-negative, HER2-positive breast cancer between 2010 and 2018 were identified from the National Cancer Database. Outcomes included receipt of stage-based guideline-concordant treatment, timely initiation of treatment (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMedicaidErb-b2 Receptor Tyrosine KinasesPatient Protection and Affordable Care ActHumansFemaleUnited StatesMiddle AgedAdultYoung AdultAdolescentTime-to-TreatmentHealth Services AccessibilityReceptors, EstrogenReceptors, Progesterone

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneERBB2 protein, human

Autor:innen und Institutionen

  • 1Surveillance and Health Equity Science, American Cancer Society, Atlanta, GA.
  • 2Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.
  • 3Aflac Cancer & Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA.
  • 4Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
  • 5Department of Oncology, Mayo Clinic, Rochester, MN.

Förderung

  • NCI NIH HHS

Zitieren

APA

Shi, K. S., Ji, X., Jiang, C., Ruddy, K. J., Castellino, S. M., Yabroff, K. R., & Han, X. (2024). Association of Medicaid Expansion With Timely Receipt of Treatment and Survival Among Patients With HR-Negative, HER2-Positive Breast Cancer. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2024.7041

Vancouver

Shi KS, Ji X, Jiang C, Ruddy KJ, Castellino SM, Yabroff KR, et al. Association of Medicaid Expansion With Timely Receipt of Treatment and Survival Among Patients With HR-Negative, HER2-Positive Breast Cancer. Journal of the National Comprehensive Cancer Network. 2024. doi:10.6004/jnccn.2024.7041

BibTeX
@article{Shi2024,
  author = {Shi, Kewei Sylvia and Ji, Xu and Jiang, Changchuan and Ruddy, Kathryn J and Castellino, Sharon M and Yabroff, K Robin and Han, Xuesong},
  title = {Association of Medicaid Expansion With Timely Receipt of Treatment and Survival Among Patients With HR-Negative, HER2-Positive Breast Cancer},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2024},
  doi = {10.6004/jnccn.2024.7041}
}
Kostenlos starten →